183 related articles for article (PubMed ID: 30931483)
1. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation.
Dursun N; Akarsu M; Gokbel T; Akyuz M; Karacan C; Dursun E
J Rehabil Med; 2019 May; 51(5):390-394. PubMed ID: 30931483
[TBL] [Abstract][Full Text] [Related]
2. Botulinum Toxins Type A (Bont-A) in the Management of Lower Limb Spasticity in Children: A Systematic Literature Review and Bayesian Network Meta-analysis.
Guyot P; Kalyvas C; Mamane C; Danchenko N
J Child Neurol; 2019 Jun; 34(7):371-381. PubMed ID: 30803305
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study.
Delgado MR; Tilton A; Carranza-Del Río J; Dursun N; Bonikowski M; Aydin R; Maciag-Tymecka I; Oleszek J; Dabrowski E; Grandoulier AS; Picaut P;
Dev Med Child Neurol; 2021 May; 63(5):592-600. PubMed ID: 33206382
[TBL] [Abstract][Full Text] [Related]
4. AbobotulinumtoxinA Efficacy and Safety in Children With Equinus Foot Previously Treated With Botulinum Toxin.
Dabrowski E; Bonikowski M; Gormley M; Volteau M; Picaut P; Delgado MR
Pediatr Neurol; 2018 May; 82():44-49. PubMed ID: 29625849
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.
Tapias G; García-Romero M; Crespo C; Cuesta M; Forné C; Pascual-Pascual SI
Farm Hosp; 2016 Sep; 40(5):412-26. PubMed ID: 27570991
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada.
Johnston K; Danchenko N; Hansen R; Dinet J; Liovas A; Armstrong A; Bains S; Sullivan SD
J Med Econ; 2020 Jun; 23(6):631-640. PubMed ID: 31985313
[No Abstract] [Full Text] [Related]
7. AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity.
Syed YY
Paediatr Drugs; 2017 Aug; 19(4):367-373. PubMed ID: 28623614
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.
Marciniak C; McAllister P; Walker H; Brashear A; Edgley S; Deltombe T; Khatkova S; Banach M; Gul F; Vilain C; Picaut P; Grandoulier AS; Gracies JM;
PM R; 2017 Dec; 9(12):1181-1190. PubMed ID: 28625615
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy.
Delgado MR; Bonikowski M; Carranza J; Dabrowski E; Matthews D; Russman B; Tilton A; Velez JC; Grandoulier AS; Picaut P
J Child Neurol; 2017 Nov; 32(13):1058-1064. PubMed ID: 28914131
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Repeat AbobotulinumtoxinA (Dysport®) Injections in Improving Gait in Children with Spastic Cerebral Palsy.
Dursun N; Bonikowski M; Dabrowski E; Matthews D; Gormley M; Tilton A; Carranza J; Grandoulier AS; Picaut P; Delgado MR
Dev Neurorehabil; 2020 Aug; 23(6):368-374. PubMed ID: 31691605
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
[TBL] [Abstract][Full Text] [Related]
12. Real-world differences in dosing and clinical utilization of OnabotulinumtoxinA and AbobotulinumtoxinA in the treatment of upper limb spasticity.
Bohart Z; Dashtipour K; Kim H; Schwartz M; Zuzek A; Singh R; Nelson M
Toxicon; 2024 Apr; 241():107678. PubMed ID: 38447766
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
Gracies JM; Esquenazi A; Brashear A; Banach M; Kocer S; Jech R; Khatkova S; Benetin J; Vecchio M; McAllister P; Ilkowski J; Ochudlo S; Catus F; Grandoulier AS; Vilain C; Picaut P;
Neurology; 2017 Nov; 89(22):2245-2253. PubMed ID: 29093068
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].
Kurenkov AL; Klochkova OA; Bursagova BI; Karimova HM; Kuzenkova LM; Mamedyarov AM; Namazova-Baranova LS; Agranovich OV; Agranovich AO; Soboleva OA; Khapaeva MM; Batysheva TT; Sarzhina MN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):37-44. PubMed ID: 29265085
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial.
Dimitrova R; Kim H; Meilahn J; Chambers HG; Racette BA; Bonikowski M; Park ES; McCusker E; Liu C; Brin MF
NeuroRehabilitation; 2022; 50(1):33-46. PubMed ID: 34957954
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
Carraro E; Trevisi E; Martinuzzi A
Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
[TBL] [Abstract][Full Text] [Related]
17. AbobotulinumtoxinA (Dysport
Tilton A; Russman B; Aydin R; Dincer U; Escobar RG; Kutlay S; Lipczyk Z; Velez JC; Grandoulier AS; Tse A; Picaut P; Delgado MR
J Child Neurol; 2017 Apr; 32(5):482-487. PubMed ID: 28068857
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular Botulinum toxin-A injections.
Read FA; Boyd RN; Barber LA
Res Dev Disabil; 2017 Sep; 68():35-41. PubMed ID: 28735160
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial.
Esquenazi A; Stoquart G; Hedera P; Jacinto LJ; Dimanico U; Constant-Boyer F; Brashear A; Grandoulier AS; Vilain C; Picaut P; Gracies JM
PM R; 2020 Sep; 12(9):853-860. PubMed ID: 32108436
[TBL] [Abstract][Full Text] [Related]
20. Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
Jog M; Wein T; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2016 Sep; 43(5):687-96. PubMed ID: 27430524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
